ライフサイエンスコーパス: atrial natriuretic peptide

1 ic* and pulmonary* vascular resistances, and atrial natriuretic peptide*.

2 the NEP-dependent degradation of vasodilator atrial natriuretic peptide.

3 c protease responsible for the activation of atrial natriuretic peptide.

4 described stable fragment of N-terminal pro-atrial natriuretic peptide.

5 tion of the cardiac-derived peptide hormone, atrial natriuretic peptide.

6 that degrades vasoactive peptides, including atrial natriuretic peptide.

7 lar results were obtained for N-terminal pro-atrial natriuretic peptide.

8 ibute to the breakdown of bradykinin and the atrial natriuretic peptide.

9 mall peptides such as insulin, glucagon, and atrial natriuretic peptide.

10 Mz-ChA-1 responded only to atrial natriuretic peptide.

11 ypoxia can induce synthesis and secretion of atrial natriuretic peptide.

12 aritide is a 25-amino-acid synthetic form of atrial natriuretic peptide.

13 ing in the presence of chronically increased atrial natriuretic peptide.

14 -type natriuretic peptide in comparison with atrial natriuretic peptide.

15 e of chronically increased concentrations of atrial natriuretic peptide.

16 sue weight assessment and gene expression of atrial natriuretic peptide.

17 All patients showed low serum levels of atrial natriuretic peptide.

18 re healthy and demonstrated normal levels of atrial natriuretic peptide.

19 r function, and severely decreased levels of atrial natriuretic peptide.

20 cant even after adjusting for N-terminal pro-atrial natriuretic peptide.

21 ous frameshift mutation in the gene encoding atrial natriuretic peptide.

22 eptide was significantly more effective than atrial natriuretic peptide (16-fold increase in cyclic G

23 ose of SDZ-WAG 994, significant increases in atrial natriuretic peptide (216 +/- 137 to 407 +/- 146 p

24 intact internal mammary artery, 1 microM of atrial natriuretic peptide (26-fold increase in cyclic G

25 in -26%; aldosterone -32%; vasopressin -30%; atrial natriuretic peptide -27%).

26 C resulted in marked increases of myocardial atrial natriuretic peptide 4-hydroxy-2-nonenal (a marker

27 r greater, P=0.001), had increased levels of atrial natriuretic peptide (7.3 versus 4.9 pmol/L, P=0.0

28 t converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regul

29 converts pro-atrial natriuretic peptide into atrial natriuretic peptide, a cardiac hormone that regul

30 Atrial natriuretic peptide, a hormone synthesized by the

31 mRNA from LV myocytes showed upregulation of atrial natriuretic peptide, a molecular marker of hypert

32 ms of natriuretic peptide receptors but that atrial natriuretic peptide acts primarily on the artery

33 n plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP exc

34 , B-type natriuretic peptide, N-terminal pro-atrial natriuretic peptide, aldosterone, renin, fibrinog

35 ohumoral factors, cytokines, endothelin, and atrial natriuretic peptide all may participate in HPA ax

36 n-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could

37 ) of cardiac-specific genes (Nkx2.5, GATA-4, atrial natriuretic peptide, alpha- and beta-myosin heavy

38 Atrial natriuretic peptide also prevented stimulation of

39 Brain natriuretic peptide and atrial natriuretic peptide also released norepinephrine

40 leation, molecular up-regulation of released atrial natriuretic peptide, altered expression of classi

41 ion of the fetal gene program (ie, increased atrial natriuretic peptide and alpha skeletal actin gene

42 n human ventricles (n=13), message levels of atrial natriuretic peptide and AT(1) receptor were inver

43 for age and clinical covariates, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

44 In men, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

45 rdiovascular regulator that is stimulated by atrial natriuretic peptide and B-type natriuretic peptid

46 Atrial natriuretic peptide and B-type natriuretic peptid

47 ions of natriuretic peptides (N-terminal pro-atrial natriuretic peptide and B-type natriuretic peptid

48 s less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptid

49 eased expression of cardiac embryonic genes (atrial natriuretic peptide and beta-myosin heavy chain)

50 logical properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide

51 NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide

52 In competition binding experiments, atrial natriuretic peptide and brain type natriuretic pe

53 thod to quantitate mRNA expression levels of atrial natriuretic peptide and c-fos in an in vitro mode

54 The binding of atrial natriuretic peptide and C-type natriuretic peptid

55 Other substrates of IDE such as atrial natriuretic peptide and glucagon also competitive

56 llows a stepwise pattern, with resistance to atrial natriuretic peptide and marked sympathetic activa

57 s opposite effects, as do excess circulating atrial natriuretic peptide and overactivity of various i

58 ated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress mark

59 y overcoming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting Na-H exchanger

60 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic

61 he expression of known hypertrophic markers (atrial natriuretic peptide) and transcription factor act

62 etic peptides (C-type natriuretic peptide >> atrial natriuretic peptide) and, to a much smaller exten

63 nosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine.

64 n, we found that norepinephrine, endothelin, atrial natriuretic peptide, and bradykinin had no signif

65 ion, LVEF, serum ACE, plasma angiotensin II, atrial natriuretic peptide, and brain natriuretic peptid

66 protein synthesis, cellular protein, prepro-atrial natriuretic peptide, and c-fos mRNAs and decrease

67 m salt (DEA/NO) or the natriuretic peptides, atrial natriuretic peptide, and C-type natriuretic pepti

68 itivities of their cGMP responses to DEA/NO, atrial natriuretic peptide, and C-type natriuretic pepti

69 rations for histology, middle neurofilament, atrial natriuretic peptide, and connexin (Cx) 43 reveale

70 agents at this time appear to be adenosine, atrial natriuretic peptide, and cyclosporine, with other

71 tches, the response of BKCa to nitric oxide, atrial natriuretic peptide, and dibutyryl cGMP (Bt2cGMP)

72 only marginally elevated by the addition of atrial natriuretic peptide, and in broken-cell preparati

73 ulate whereas somatostatin, cholecystokinin, atrial natriuretic peptide, and nitric oxide inhibit aci

74 ene-related peptide, adrenomedullin, amylin, atrial natriuretic peptide, and pituitary adenylate cycl

75 or norepinephrine, epinephrine, aldosterone, atrial natriuretic peptide, and plasma renin activity we

76 mic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (concentration r

77 for reduced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lip

78 lective PDE2 inhibitor BAY 60-7550 augmented atrial natriuretic peptide- and treprostinil-evoked pulm

79 Atrial natriuretic peptide (ANP) acts acutely to reduce

80 e-A (GC-A) receptor is known to require both atrial natriuretic peptide (ANP) and an adenine nucleoti

81 used to map the antagonistic effects between atrial natriuretic peptide (ANP) and angiotensin II (Ang

82 the EGR1-regulated cardioprotective peptides atrial natriuretic peptide (ANP) and B-type natriuretic

83 Cardiomyocytes secrete atrial natriuretic peptide (ANP) and B-type natriuretic

84 The cardiac natriuretic peptides (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic

85 of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain nat

86 Atrial natriuretic peptide (ANP) and brain natriuretic p

87 ctivation of a fetal gene program, including atrial natriuretic peptide (ANP) and brain natriuretic p

88 at baseline, messenger ribonucleic acid for atrial natriuretic peptide (ANP) and brain natriuretic p

89 referred to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type nat

90 , the expression of iNOS mRNA was induced by atrial natriuretic peptide (ANP) and C-type natriuretic

91 Physiological actions of atrial natriuretic peptide (ANP) and C-type natriuretic

92 Both atrial natriuretic peptide (ANP) and C-type natriuretic

93 The effect of atrial natriuretic peptide (ANP) and cyclic nucleotides

94 ct (IMCD) cells contributes to resistance to atrial natriuretic peptide (ANP) and the excessive sodiu

95 ntrations of plasma norepinephrine (PNE) and atrial natriuretic peptide (ANP) and the renin activity

96 Subnanomolar concentrations of atrial natriuretic peptide (ANP) and type C natriuretic

97 he natriuretic signaling pathway in RPE with atrial natriuretic peptide (ANP) and with membrane-perme

98 pertensive rat, implicated the gene encoding atrial natriuretic peptide (ANP) as a possible candidate

99 Atrial natriuretic peptide (ANP) binding sites have been

100 After atrial natriuretic peptide (ANP) binding to NPRA, ligand

101 o mediate its desensitization in response to atrial natriuretic peptide (ANP) binding.

102 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

103 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

104 GMP, 1-methyl-3-isobutylxanthine (IBMX), and atrial natriuretic peptide (ANP) but not 8-Br-cAMP mimic

105 ed the hypothesis that nitric oxide (NO) and atrial natriuretic peptide (ANP) can attenuate the effec

106 Atrial natriuretic peptide (ANP) can inhibit the release

107 in natriuretic peptide A (NPPA) encoding the atrial natriuretic peptide (ANP) causes inflammation, fi

108 ion (VE) natriuresis and renal resistance to atrial natriuretic peptide (ANP) characterize states of

109 Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patie

110 Corin is a recently discovered pro-atrial natriuretic peptide (ANP) convertase that is abun

111 cardiac serine protease that acts as the pro-atrial natriuretic peptide (ANP) convertase.

112 Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effe

113 Atrial natriuretic peptide (ANP) depresses contractility

114 ibited hypertrophy concurrent with increased atrial natriuretic peptide (ANP) expression that depende

115 mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% incre

116 Activation of the atrial natriuretic peptide (ANP) gene is regarded as one

117 with Src, modulated basal and ET-stimulated atrial natriuretic peptide (ANP) gene promoter activity,

118 tudy was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronar

119 ciated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene.

120 mulated contractility, whereas 10 micromol/L atrial natriuretic peptide (ANP) had no effect.

121 Atrial natriuretic peptide (ANP) has a central role in r

122 The atrial natriuretic peptide (ANP) hormone is secreted by

123 The role of atrial natriuretic peptide (ANP) in regulating fetal car

124 osure to 3-morpholino-sydnonimine (SIN-1) or atrial natriuretic peptide (ANP) in the absence or in th

125 e main receptor that mediates the effects of atrial natriuretic peptide (ANP) in the regulation of pl

126 assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide (ANP) induced synthesis of in

127 Atrial natriuretic peptide (ANP) influences glucose home

128 Atrial natriuretic peptide (ANP) inhibited VPF signaling

129 Atrial natriuretic peptide (ANP) inhibits the proliferat

130 The cardiac hormone atrial natriuretic peptide (ANP) is a 28-amino acid (AA)

131 Atrial natriuretic peptide (ANP) is a cardiac hormone es

132 Atrial natriuretic peptide (ANP) is a cardiac hormone th

133 Atrial natriuretic peptide (ANP) is a hormone involved i

134 Atrial natriuretic peptide (ANP) is a hormone with diure

135 Atrial natriuretic peptide (ANP) is a hormone with numer

136 Atrial natriuretic peptide (ANP) is a peptide hormone th

137 The receptor for atrial natriuretic peptide (ANP) is a type-I transmembra

138 Atrial natriuretic peptide (ANP) is an endogenous peptid

139 Although atrial natriuretic peptide (ANP) is not amidated, Pam ex

140 We have previously shown that atrial natriuretic peptide (ANP) is present in caveolae

141 Atrial natriuretic peptide (ANP) is synthesized in the k

142 ug 44b administered at 10 mg/kg po on plasma atrial natriuretic peptide (ANP) levels in conscious rat

143 failure is characterized by elevated plasma atrial natriuretic peptide (ANP) levels, but little is k

144 nd norepinephrine (NE) increased both OP and atrial natriuretic peptide (ANP) mRNA levels twofold to

145 of this study was to examine the effects of atrial natriuretic peptide (ANP) on cytosolic Ca2+ oscil

146 the impact of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) on sodium homeostasis i

147 intravital microscopy to study the effect of atrial natriuretic peptide (ANP) on the extrasplenic mic

148 the major and possibly the only receptor for atrial natriuretic peptide (ANP) or B-type natriuretic p

149 Atrial natriuretic peptide (ANP) or B-type natriuretic p

150 Cyclic GMP (cGMP) made in response to atrial natriuretic peptide (ANP) or nitric oxide (NO) is

151 orskolin), we found that low doses of either atrial natriuretic peptide (ANP) or NO donors potentiate

152 Disruption of the atrial natriuretic peptide (ANP) receptor [guanylyl cycl

153 extracellular hormone binding domain of the atrial natriuretic peptide (ANP) receptor contains two p

154 The atrial natriuretic peptide (ANP) receptor is a 130-kDa t

155 The most studied member is the atrial natriuretic peptide (ANP) receptor, which is invo

156 y and guanylyl cyclase catalytic) domains of atrial natriuretic peptide (ANP) receptor-A (Npra) in po

157 Plasma volume fell, and plasma atrial natriuretic peptide (ANP) rose, after LPS adminis

158 st that oxytocin may mediate stretch-induced atrial natriuretic peptide (ANP) secretion.

159 ism for antiapoptotic signaling initiated by atrial natriuretic peptide (ANP) stimulation leading to

160 ier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular pe

161 Atrial natriuretic peptide (ANP) via its guanylyl cyclas

162 Circulating chimeric atrial natriuretic peptide (ANP) was detected in high co

163 ive partition analysis indicated that (125)I-atrial natriuretic peptide (ANP) was rapidly released in

164 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently geneticall

165 ition, plasma arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) were determined at the

166 enzyme) is a cardiac protease that activates atrial natriuretic peptide (ANP), a cardiac hormone that

167 nd treat systemic hypertension by expressing atrial natriuretic peptide (ANP), a hormone able to decr

168 RP17 in cardiomyocytes enhances secretion of atrial natriuretic peptide (ANP), a regulator of blood p

169 al structures of the complexes of NPR-C with atrial natriuretic peptide (ANP), and with brain natriur

170 Concentrations of atrial natriuretic peptide (ANP), brain natriuretic pept

171 Atrial natriuretic peptide (ANP), C-type natriuretic pep

172 translated region of NPPA, the gene encoding atrial natriuretic peptide (ANP), is associated with blo

173 blood pressure and fluid homeostasis by the atrial natriuretic peptide (ANP), making PDE2-type enzym

174 nous neuropeptides, endothelin-3 (ET-3), and atrial natriuretic peptide (ANP), modulate the prolifera

175 The receptor for atrial natriuretic peptide (ANP), natriuretic peptide re

176 A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in

177 Atrial natriuretic peptide (ANP), relaxin, glucagon, pro

178 pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin

179 ases in vascular permeability in response to atrial natriuretic peptide (ANP), which acts with the ki

180 GC) activity of the receptor protein in both atrial natriuretic peptide (ANP)-dependent and -independ

181 Nitric oxide (NO)- and atrial natriuretic peptide (ANP)-initiated cGMP signalin

182 exin A6 (Anxa6) to be a crucial regulator of atrial natriuretic peptide (ANP)-mediated counterhypertr

183 component of the intracellular modulation of atrial natriuretic peptide (ANP)-stimulated activation o

184 an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

185 production of vasodilatory peptides, such as atrial natriuretic peptide (ANP).

186 uanylate cyclase that acts as a receptor for atrial natriuretic peptide (ANP).

187 ene expression and production and release of atrial natriuretic peptide (ANP).

188 y and degrades natriuretic peptides, such as atrial natriuretic peptide (ANP).

189 p between ADH secretion and the secretion of atrial natriuretic peptide (ANP).

190 enous neuropeptides, endothelin-3 (ET-3) and atrial natriuretic peptide (ANP).

191 tor A (NPR-A) is the biological receptor for atrial natriuretic peptide (ANP).

192 onse both to volume expansion and to infused atrial natriuretic peptide (ANP).

193 blunted natriuretic and diuretic response to atrial natriuretic peptide (ANP).

194 ct mRNA and to detect expression of iNOS and atrial natriuretic peptide (ANP).

195 ular leak can be prevented by treatment with atrial natriuretic peptide (ANP).

196 ATA4) that encodes a transcription factor of atrial natriuretic peptide (ANP).

197 udy tested the hypothesis that activation of atrial natriuretic peptide (ANP)/cGMP/protein kinase G s

198 ngiotensin II (ANG II; vasoconstrictive) and atrial natriuretic peptide (ANP; vasodilatory) antagoniz

199 lamines, renin, aldosterone, angiotensin and atrial natriuretic peptides (ANP, N-ANP and BNP) were me

200 Moreover, while levels of mRNA encoding atrial natriuretic peptide are reduced in E17.5 GR(-/-)

201 contribute) is the key process through which atrial natriuretic peptide attenuates elevations in cyto

202 ales, cardiac expression of the precursor of atrial natriuretic peptide B and of adrenomedullin also

203 neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.

204 assessed the relations of plasma N-terminal atrial natriuretic peptide, B-type natriuretic peptide,

205 l, carbonyls), hypertrophic gene expression (atrial natriuretic peptide, B-type natriuretic peptide,

206 tricular expressions of the genes coding for atrial natriuretic peptide, beta myosin heavy chain, med

207 levels by more than 50% within 3 h and 125I-atrial natriuretic peptide binding by approximately 50%

208 all thickness, increased lung levels of ANP (atrial natriuretic peptide), BNP (brain-type natriuretic

209 g expression of the hypertrophy gene markers atrial natriuretic peptide, brain natriuretic peptide, b

210 Synthetic atrial natriuretic peptide (carperitide) and B-type natr

211 or-stimulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardi

212 The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase.

213 Corin (also known as atrial natriuretic peptide-converting enzyme) is a cardi

214 This report implicates perturbation of the atrial natriuretic peptide-cyclic guanosine monophosphat

215 g both the renin-angiotensin-aldosterone and atrial natriuretic peptide-degrading systems simultaneou

216 f rats with RO-25-6760 for 7 d increased the atrial natriuretic peptide-dependent excretion of sodium

217 Atrial natriuretic peptide-dependent guanylate cyclase a

218 We show that atrial natriuretic peptide does not modulate the release

219 ressed in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by sp

220 the addition of cGMP intracellularly, or of atrial natriuretic peptide extracellularly, stimulated i

221 guanylyl cyclase-A (GC-A), the receptor for atrial natriuretic peptide, five are conserved within GC

222 Phase 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the

223 iogenesis, increased Akt activity, decreased atrial natriuretic peptide gene expression, and maintena

224 ed with the negative regulation of the human atrial natriuretic peptide gene promoter by these mutant

225 ntricular myocytes, with increased secretory atrial natriuretic peptide granules and degenerative mye

226 ed the effect of Ras overexpression on human atrial natriuretic peptide (hANP) gene expression, a mar

227 ns, the most intriguing have been the use of atrial natriuretic peptide in patients with nonoliguric

228 angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the exercise and control g

229 angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the training and control g

230 mm(2), P < 0.01) and marker gene expression (atrial natriuretic peptide increased by 409 +/- 32%, and

231 Finally, we revealed that atrial natriuretic peptide increased phosphorylation of

232 rprisingly, L-CPT1 hearts contained elevated atrial natriuretic peptide, indicating induction of hype

233 lls, both the NO donor S-nitrosocysteine and atrial natriuretic peptide induced SSG1 phosphorylation,

234 xpressed in cardiomyocytes that converts pro-atrial natriuretic peptide into atrial natriuretic pepti

235 Atrial natriuretic peptide is a circulating hormone that

236 Midregional pro-atrial natriuretic peptide is a newly described stable f

237 Midregional pro-atrial natriuretic peptide is a powerful predictor of ad

238 rdiomyocytes expression of the stress-marker atrial natriuretic peptide is suppressed by EMD 57033.

239 An increase in the PR interval and atrial natriuretic peptide level, consistent with adenos

240 he placebo group, P=.001) and reduced plasma atrial natriuretic peptide levels (-2.9 versus 26.9 pg/m

241 .05) while concurrently reducing circulating atrial natriuretic peptide levels (p < 0.01).

242 The reductions in vasopressin and atrial natriuretic peptide levels after captopril did no

243 potential therapeutic applications of mutant atrial natriuretic peptide (mANP).

244 Midregional pro-atrial natriuretic peptide may represent a clinically us

245 odilatin, the renally synthesized isoform of atrial natriuretic peptide, may improve pulmonary conges

246 ulate the reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertroph

247 The increased atrial natriuretic peptide most likely results in extrac

248 s the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis

249 enomedullin (MR-proADM), and midregional pro-atrial natriuretic peptide (MR-proANP) in a large prospe

250 sess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients after

251 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-

252 1-receptor mRNA and protein, upregulation of atrial natriuretic peptide mRNA expression, and increase

253 of diastolic function, nor the induction in atrial natriuretic peptide mRNA in the hypertrophic vent

254 ells expressed middle neurofilament (but not atrial natriuretic peptide) mRNA and protein.

255 gical domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic p

256 action of numerous other regulators such as atrial natriuretic peptide, neurotensin, and orexin B ar

257 n effect further enhanced in the presence of atrial natriuretic peptide, NO, and treprostinil.

258 n AMI is the increased cardiac expression of atrial natriuretic peptide (NP) and B-type NP, with thei

259 gated the effectiveness of plasma N-terminal atrial natriuretic peptide (NT-ANP) and brain natriureti

260 of this study was to examine the effects of atrial natriuretic peptide on potentially harmful elevat

261 th increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment

262 in men, P<0.001 in women) and N-terminal pro-atrial natriuretic peptide (P<0.001 in men, P=0.001 in w

263 ase in cyclic GMP in response to 1 microM of atrial natriuretic peptide, p < .05).

264 one (NT-pro-BNP), and N-terminal fragment of atrial natriuretic peptide pro-hormone (NT-pro-ANP) leve

265 93 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuret

266 In cell-based studies, corin converted pro-atrial natriuretic peptide (pro-ANP) to mature ANP, sugg

267 e hypertension, and corin activation and pro-atrial natriuretic peptide processing activity were unde

268 ented corin activation and inhibited its pro-atrial natriuretic peptide processing activity.

269 hese pathways, related to the stimulation of atrial natriuretic peptide production and secretion.

270 iously undiscovered, mechanism through which atrial natriuretic peptide protects rat hepatocytes, and

271 tic peptide receptor 1 gene, encoding NPR-A, atrial natriuretic peptide receptor 1) was recently show

272 two categorically different models (lack of atrial natriuretic peptide receptor A; overexpression of

273 talized in myocytes, as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-28

274 tetratricopeptide repeat (TPR) domain to the atrial natriuretic peptide receptor.

275 The atrial natriuretic peptide secreted by atrial myocytes i

276 sues and [3H]phenylalanine incorporation and atrial natriuretic peptide secretion as markers of hyper

277 termined by indices of protein synthesis and atrial natriuretic peptide secretion.

278 , V12rac1 expression leads to an increase in atrial natriuretic peptide secretion.

279 gregate (amylin, ACTH, LHRH, angiotensin II, atrial natriuretic peptide, somatostatin, oxytocin, neur

280 PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the restin

281 3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone bind

282 We show that atrial natriuretic peptide, through protein kinase G, at

283 It converts pro-atrial natriuretic peptide to atrial natriuretic peptide

284 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any

285 Atrial natriuretic peptide together with PDE9a inhibitor

286 e was 24% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 16% lower (P<0.001); in w

287 e was 29% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 18% lower (P<0.001).

288 Atrial natriuretic peptide was found to be up-regulated

289 ncluded vasoactive peptides; the vasodilator atrial natriuretic peptide was induced by CSD, while the

290 - or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young ve

291 f response to C-type natriuretic peptide and atrial natriuretic peptide was the same as in the intact

292 gic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantita

293 s, extracellular matrix (ECM), integrin, and atrial natriuretic peptide were assessed.

294 s-sectional area, and the expression of ANP (atrial natriuretic peptide) were significantly attenuate

295 the approximately 180-kDa fragment activated atrial natriuretic peptide, whereas the approximately 16

296 NO donors on COX-2-mRNA expression; and (c) atrial natriuretic peptide, which increases cellular cGM

297 However, the atrial natriuretic peptide, which is induced during left

298 mplants to produce sufficient amounts of the atrial natriuretic peptide, which reduced the blood pres

299 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide with metabolic risk factors,

300 estry, and identified associations of plasma atrial natriuretic peptide with rs5068 (P = 8 x 10(-70))